Canadian pilot study suggests prescription icosapent ethyl (VASCEPA®) might improve symptoms of COVID-19 and reduce inflammation
The results of a Canadian study released this weekend provides encouraging data suggesting that the prescription strength omega-3 called icosapent ethyl (VASCEPA) may reduce inflammation and improve symptoms in patients with a diagnosis of COVID-19. “This study provides the first evidence of an early anti-inflammatory effect of icosapent ethyl in symptomatic COVID-19 positive outpatients – […]
